Literature DB >> 16556846

Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells.

Anish Suri1, Boris Calderon, Thomas J Esparza, Katherine Frederick, Patrice Bittner, Emil R Unanue.   

Abstract

Type 1 diabetes mellitus results from the autoimmune destruction of the beta cells of the pancreatic islets of Langerhans and is recapitulated in the nonobese diabetic strain of mice. In an attempt to rescue islet loss, diabetic mice were made normoglycemic by islet transplantation and immunization with Freund's complete adjuvant along with multiple injections of allogeneic male splenocytes. This treatment allowed for survival of transplanted islets and recovery of endogenous beta cell function in a proportion of mice, but with no evidence for allogeneic splenocyte-derived differentiation of new islet beta cells. Control of the autoimmune disease at a crucial time in diabetogenesis can result in recovery of beta cell function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556846     DOI: 10.1126/science.1123500

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  30 in total

1.  Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.

Authors:  Richard A O'Connor; Xujian Li; Seth Blumerman; Stephen M Anderton; Randolph J Noelle; Dyana K Dalton
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 2.  Cellular therapies for type 1 diabetes.

Authors:  D D Lee; E Grossman; A S Chong
Journal:  Horm Metab Res       Date:  2008-02       Impact factor: 2.936

3.  The current status of islet transplantation and its perspectives.

Authors:  Naoya Kobayashi
Journal:  Rev Diabet Stud       Date:  2008-11-10

4.  Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes.

Authors:  J J Meier; J C Lin; A E Butler; R Galasso; D S Martinez; P C Butler
Journal:  Diabetologia       Date:  2006-06-27       Impact factor: 10.122

Review 5.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

6.  Centroacinar Cells Are Progenitors That Contribute to Endocrine Pancreas Regeneration.

Authors:  Fabien Delaspre; Rebecca L Beer; Meritxell Rovira; Wei Huang; Guangliang Wang; Stephen Gee; Maria del Carmen Vitery; Sarah J Wheelan; Michael J Parsons
Journal:  Diabetes       Date:  2015-07-07       Impact factor: 9.461

7.  Anti-diabetic effect of a novel oligosaccharide isolated from Rosa canina via modulation of DNA methylation in Streptozotocin-diabetic rats.

Authors:  Gholamreza Bahrami; Soraya Sajadimajd; Bahareh Mohammadi; Razieh Hatami; Shahram Miraghaee; Samira Keshavarzi; Mozafar Khazaei; Seyed Hamid Madani
Journal:  Daru       Date:  2020-08-03       Impact factor: 3.117

8.  Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.

Authors:  Francesca Fallarino; Giovanni Luca; Mario Calvitti; Francesca Mancuso; Claudio Nastruzzi; Maria C Fioretti; Ursula Grohmann; Ennio Becchetti; Anne Burgevin; Roland Kratzer; Peter van Endert; Louis Boon; Paolo Puccetti; Riccardo Calafiore
Journal:  J Exp Med       Date:  2009-10-12       Impact factor: 14.307

9.  Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.

Authors:  Matthew J Parker; Song Xue; John J Alexander; Clive H Wasserfall; Martha L Campbell-Thompson; Manuela Battaglia; Silvia Gregori; Clayton E Mathews; Sihong Song; Misty Troutt; Scott Eisenbeis; John Williams; Desmond A Schatz; Michael J Haller; Mark A Atkinson
Journal:  Diabetes       Date:  2009-07-23       Impact factor: 9.461

Review 10.  Slow and steady is the key to beta-cell replication.

Authors:  Kristen Brennand; Doug Melton
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.